Q-omics provides the consensus-scored SHOC1 profile across patient tissues and cancer cell-line models. SHOC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SHOC1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SHOC1 RNA expression shows 17,395 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where SHOC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHOC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHOC1 survival associations across molecular data types. SHOC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHOC1 RNA expression–survival associations across cancer types. High SHOC1 expression shows unfavorable associations in KIRC, ACC, MESO and BLCA, but favorable associations in CESC and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SHOC1 RNA expression.
This table summarizes SHOC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SHOC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHOC1 shows lower tumor expression in KIRC and KIRP and higher tumor expression in LUAD, HNSC, LUSC and BLCA. The KIRC box plot shows higher SHOC1 RNA expression in normal versus tumor tissue (log2 FC = −1.221, t-test p < 0.001).
This table shows molecular features associated with SHOC1 in patient tissues and cancer cell lines. In patient samples, SHOC1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SHOC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
